Friday, March 19, 2010

The aggressive use of retroviral therapies has been able to bring many HIV+ men's viral load down to undetectable levels


New Study Quantifies HIV Infection Risk

BY L.K. REGAN
PUBLISHED MAR 04, 2010
The aggressive use of retroviral therapies has been able to bring many HIV+ men's viral load down to undetectable levels. But until now, it has been unclear whether those medications reduce the risk of infection for those men's sexual partners. Now, a recent study from Australia specifically quantifies how likely a man is to contract HIV from a given sex act—and demonstrates that those risks are barely impacted by contemporary treatment methods.

The study was conducted by researchers at the National Center in HIV Epidemiology and Clinical Research at the University of New South Wales in Darlinghurst, Australia. The researchers studied 1,427 men between 2001 and 2004 who reported having sex with another man at least once in the previous five years. Every six months the subjects were interviewed about their sexual activity and until 2007 tested for HIV. Researchers were interested in relating their results to findings of an American study done in the 1990s, which found an 0.82 percent risk of contracting HIV for every instance of receptive anal sex. But in a result that the study's authors describe as "unexpected," the new study found a slightly higher rate of infection—1.43 percent per instance of receptive anal sex—meaning that the theory that reduced viral loads would make the virus less transmissible appears to be wrong.

That is a disappointing outcome. But within the study's results lies some interesting information quantifying the risk involved in a given sex act. It looks like this: The risk of becoming infected on any single occasion of receptive anal sex with internal ejaculation is 1.43 percent. If the partner withdraws before ejaculating, that risk goes down to 0.65 percent. The infection rate for each occasion of insertive anal sex (topping) is 0.11 percent if a man is circumcised; it goes up to 0.62 percent if a man is uncircumcised. The upshot: receptive anal sex with ejaculation is roughly twice as risky as receptive anal sex with pre-ejaculation withdrawal or topping by an uncircumcised man, and more than 10 times as risky as topping by a circumcised man.

Why should gay men look closely at these numbers? The study's authors warn that "caution should be exercised before interpreting the results at the level of individual men." But blogger and journalist Chris Crain, blogging at Citizen Crain puts a different spin on this study: "I tried for years when I edited the Washington Blade and a number of other gay publications to get this kind of straightforward info about the risk associated with various sexual acts," he writes. "We were, for the most part, stonewalled by public health 'experts' who were loathe to trust gay men with actual info, favoring instead the tired 'AIDS panic' approach of trying to scare men into using condoms by implying that any sort of sex was equally risky." In the end, more accurate information is always an improvement. http://www.realjock.com/article/1608/
 
 
FACEBOOK COMMENTS: 

Fortis: Insurer Targeted HIV Patients To Drop Coverage


 
17 Mar 2010 17:35:13 GMT
Source: Reuters

In May, 2002, Jerome Mitchell, a 17-year old college freshman from rural South Carolina, learned he had contracted HIV. The news, of course, was devastating, but Mitchell believed that he had one thing going for him: On his own initiative, in anticipation of his first year in college, he had purchased his own health insurance. 

Tuesday, March 16, 2010

AIDS drug experiment on blacks, in Washington Times by Terry Michaels


Going too far to battle disease 

Tuesday, March 16
By Terry Michael

A pharmaceutical experiment on hundreds of mostly black homosexual men and heterosexual
women in Washington is about to be undertaken by U.S. AIDS czar Dr. Anthony S. Fauci with the enthusiastic backing of the District's black mayor, Adrian M. Fenty, voiced in a January announcement. The experiment radically departs from medical "best practices" of offering antiretroviral chemotherapy for life to HIV-positive persons only after they exhibit depressed levels of CD4 T-cells and are judged to be at significant risk of contracting opportunistic illnesses associated with AIDS.

The new effort, "test and treat," as it is called, will promote universal voluntary antibody testing of adults accompanied by immediate administration of the drugs despite a wealth of evidence that the chemicals often cause serious adverse side effects - potentially life-threatening effects. However, the experiment isn't focused on individual impact. Instead, it suggests that the goal is a benefit that might accrue to society if the chemicals decrease sexual retrovirus transmission.
One of the world's leading HIV-AIDS experts, Dr. Jay A. Levy of the University of California at San Francisco, responded, "No, I wouldn't," when asked for this article if he would take the drugs if he were a homosexual black man in Washington with a positive antibody test but with normal T-cell counts and no illness.

A conservative voice for years in the drug-intervention debate, Dr. Levy wrote in an article for the San Francisco Chronicle on Feb. 23, 2001: "The persistence of HIV in cells argues for a delay in initiating antiviral treatments. Unless the infected person is sick, the very real problems of long-term treatment must be considered: toxicity which may lead to damage of the pancreas, heart, kidney or brain, emergence of resistant viruses and suppression of the body's natural anti-HIV immune responses." With words presaging the suggestion that immediate drug intervention could have societal benefits with regard to transmission, Dr. Levy wrote, "The increased prevalence of resistant viruses in newly infected people reflects the widespread use of HAART [highly active antiretroviral therapy] and the misconception that this treatment will prevent HIV transmission."
Scheduled to start midyear, according to the National Institute of Allergy and Infectious Diseases (NIAID), the experiment is based on a controversial Jan. 3, 2009 article in the British medical journal the Lancet by Dr. Reuben Granich of the World Health Organization, titled "Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model."

Director of NIAID for a quarter-century, Dr. Fauci and his director of HIV programs, Carl W. Dieffenbach, announced the experiment with Mr. Fenty on Jan. 12 as part of a larger, $26.4 million study to combat what the District's HIV-AIDS agency claims is a "generalized epidemic" affecting 3 percent of adults and adolescents. Use of the word "epidemic" suggests widespread disease and mortality, though the vast majority of the agency's claimed cases have tested positive only for HIV antibodies and have experienced no illness from AIDS. Research shows "untreated" positives may not experience illness following an HIV test for 10, 15 or 20 years - or ever, in many documented cases.
Dr. Fauci and Mr. Dieffenbach published an article in the June 10, 2009 edition of the Journal of the American Medical Association in laudatory response to Dr. Granich's article. "A recent modeling study... reaches provocative conclusions and provides the theoretical basis for a new and potentially important public health policy strategy," they wrote. "This approach, referred to as 'test and treat,' predicts that [with] implementation of an annual voluntary universal HIV testing program for persons older than 15 years and with immediate initiation of [antiretroviral therapy] for those individuals who test positive regardless of their CD4 T-cell count or viral load, the HIV pandemic could be reduced within 10 years."

Critical peer reviews of Dr. Granich's work were published March 28, 2009 in the Lancet, months before Dr. Fauci and Mr. Dieffenbach published their paper. One notable alarm was sounded by Dr. Harold Jaffe of the Department of Public Health at the University of Oxford: "Within the field of communicable diseases, we are aware of little precedent for the approach of 'treating for the common good.' Treatment of diseases such as tuberculosis might have the effect of decreasing transmission, but the primary goal is to decrease morbidity and mortality for the affected person."
Dr. Levy of UC-San Francisco, whose own research has received major funding from NIAID and is sometimes called the "third co-discoverer of HIV," did not directly criticize the Fauci initiative but warned that the test-and-treat theory should be reviewed by an appropriate "human subjects committee."

Statutes mandate such panels for federal projects, a reaction to the U.S. Public Health Service's infamous mid-20th-century Tuskegee study of black men and women intentionally untreated for syphilis.

The local NIAID initiative will be in collaboration with the embattled District HIV-AIDS administration, cited by a Washington Post investigation in 2009 for misallocating millions of dollars, colluding with HIV-AIDS nonprofits siphoning tax dollars for never-delivered services.
The new $26.4 million would be added to the $85 million currently spent annually by the District's HIV-AIDS agency, which employs about 160 people, up from 125 just two years ago, though the number who have died in recent years from broadly defined "AIDS" continues to decline and is little more than the few hundred annual cases of death from accidents in the District. The District HIV-AIDS administration reported that 226 people died in 2006 of AIDS or "AIDS-related" causes, which increasingly are heart, liver and other ailments from adverse effects of antiviral drug treatment. That contrasts with more than a thousand cancer deaths and a thousand who die of heart disease annually in the District.

Not only are there relatively few deaths from AIDS in the District, the number of new AIDS (not HIV) cases reported in 2007 was 648 in a jurisdiction with a total population of slightly more than a half-million. That contrasts with a total of 238 new cases of AIDS reported by Canada in 2007 for its entire population of 34 million. Somehow, there were about 128 new AIDS cases per 100,000 residents in the District, compared with 1.4 per 100,000 in all of Canada - a 9,000 percent difference.
Either Canada is really bad at collecting numbers for an apparently sexually transmitted disease, District residents are hypersexually active, or the District's HIV-AIDS "epidemic" is grossly overstated by an agency charged with ineptness for years and always interested in sustaining its mission and budget.
Terry Michael is a Washington writer. http://www.washingtontimes.com/news/2010/mar/17/going-too-far-to-battle-disease/